PARSIPPANY, N.J. & TEL AVIV & PARIS--(BUSINESS WIRE)--ACCESS HERE THE COMPLETE PRESS RELEASE Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), and ...
Cabotegravir demonstrated efficacy as a long-acting PrEP, with no new HIV cases in the PILLAR trial over 12 months. The combination of cabotegravir and rilpivirine showed high viral suppression rates ...
MUMBAI, India and NAPLES, Fla., Nov. 14, 2025 /PRNewswire/ -- Global pharma major Lupin Limited (Lupin) (BSE: 500257) (NSE: LUPIN) (REUTERS: LUPIN.BO) (BLOOMBERG: LPCIN) today announced the launch of ...
First Long-Acting Injectable HIV Treatment Works Better Than Daily Pills For Some Patients, GSK Says
British pharma giant GSK on Wednesday announced promising results for a long-acting injectable HIV therapy, offering a hopeful alternative for people who take daily pills to halt the virus’s ...
Patients who struggle to take daily HIV pills can benefit from long-acting injectable treatments, a new study by researchers at UC San Francisco has found. The strategy could also help stop the spread ...
Introduction Maximising the impact of new and forthcoming long-acting injectable HIV pre-exposure prophylaxis (PrEP) products ...
Long-acting injections given once every two months can prevent HIV at least as well as daily pills for gay and bisexual men and transgender women, according to interim study results released May 18 by ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results